CD8A and neoplasm: Therefore, RGC32 exerts a synergistic effect in inhibiting tumor immunity, not only by suppressing the antigen-presenting capacity of CD8+ T lymphocytes in tumor cells, but also by hampering the proliferation of immune cells within the tumor microenvironment.